AZD0901
AZD0901 (CMG901) is an anti-CLDN18.2 antibody-drug conjugate. AZD0901 binds to CLDN18.2, undergoes internalization, disrupts microtubules, and causes direct cytotoxicity and bystander killing. AZD0901 induces ADCC and CDC through its retained IgG1 Fc. AZD0901 can be used in research on gastric or gastroesophageal junction adenocarcinoma and CLDN18.2-positive advanced solid tumors. AZD0901 consists of the antibody Sonesitatug (HY-P991026) and the toxin VcMMAE (HY-15575).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
IC50 & Target
|
CLDN18.2 |
体外実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
SMILES
N/A
-
別名
CMG901
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Keywords
- AZD0901
- CMG901
- AZD 0901
- AZD-0901
- CMG 901
- CMG-901
- Antibody-Drug Conjugates (ADCs)
- Claudin
- Microtubule/Tubulin
- Antibody-Drug Conjugates
- ADC
- ADCC
- CDC
- CLDN18.2
- IgG1 Fc
- MMAE
- advanced solid tumors
- antibody-drug conjugate
- bystander killing
- gastric or gastroesophageal junction adenocarcinoma
- microtubules
- Inhibitor
- inhibitor
- inhibit